This database contains 25 studies, archived under the term: "incidence"
Click here to filter this large number of results.
Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the Women’s Health Initiative Memory Study
Goveas, Joseph S.,
Hogan, Patricia E.,
Kotchen, Jane M.,
Smoller, Jordan W.,
Denburg, Natalie L.,
Manson, JoAnn E.,
Tummala, Aruna,
Mysiw, W. Jerry,
Ockene, Judith K.,
Woods, Nancy F.,
Espeland, Mark A.,
Wassertheil-Smoller, Sylvia
Background: Antidepressants are commonly prescribed medications in the elderly, but their relationship with incident mild cognitive impairment (MCI) and probable dementia is unknown.; Methods: The study cohort included 6,998 cognitively healthy, postmenopausal women, aged 65-79 years, who were enrolled in a hormone therapy clinical trial and had baseline depressive symptoms and antidepressant use history assessments […]
Inhaled sevoflurane may promote progression of amnestic mild cognitive impairment: a prospective, randomized parallel-group study
Liu, Yongzhe,
Pan, Ningling,
Ma, Yaqun,
Zhang, Shengshuo,
Guo, Wenzhi,
Li, Haihong,
Zhou, Jingli,
Liu, Gang,
Gao, Minglong
Background: Amnestic mild cognitive impairment (aMCI) is thought to be a transitional stage between normal aging and the development of Alzheimer’s disease (AD). Recent studies have suggested that the inhalational anesthetic isoflurane can induce caspase activation and apoptosis, increase aggregates of β-amyloid (Aβ) levels, and enhance Aβ aggregation. The aim of this study was to […]
Activity loss is associated with cognitive decline in age-related macular degeneration
Background/methods: The objective of this study was to determine whether relinquishing cognitive, physical, and social activities is associated with an increased risk of cognitive decline in patients with age-related macular degeneration (AMD). We conducted a 3-year longitudinal study of 206 nondemented patients with AMD.; Results: Twenty-three subjects (14.4%) declined cognitively. Age, sex, education, decline in […]
Vitamin D and risk of cognitive decline in elderly persons
Llewellyn, David J.,
Lang, Iain A.,
Langa, Kenneth M.,
Muniz-Terrera, Graciela,
Phillips, Caroline L.,
Cherubini, Antonio,
Ferrucci, Luigi,
Melzer, David
Background: To our knowledge, no prospective study has examined the association between vitamin D and cognitive decline or dementia.; Methods: We determined whether low levels of serum 25-hydroxyvitamin D (25[OH]D) were associated with an increased risk of substantial cognitive decline in the InCHIANTI population-based study conducted in Italy between 1998 and 2006 with follow-up assessments […]
Incidence and prediction of falls in dementia: a prospective study in older people
Background: Falls are a major cause of morbidity and mortality in dementia, but there have been no prospective studies of risk factors for falling specific to this patient population, and no successful falls intervention/prevention trials. This prospective study aimed to identify modifiable risk factors for falling in older people with mild to moderate dementia.; Methods […]
Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex
Marras, Connie,
Herrmann, Nathan,
Anderson, Geoffrey M.,
Fischer, Hadas D.,
Wang, Xuesong,
Rochon, Paula A.
Background: Differences between atypical antipsychotics in their potential to cause parkinsonism and risk factors for antipsychotic-induced parkinsonism are not well established. There is a particular paucity of information on this in real-world use of these drugs, outside of clinical trial settings.; Objective: We compared the incidence of parkinsonism after new treatment with risperidone, olanzapine, or […]
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32)
Olin, Jason T.,
Bhatnagar, Vinod,
Reyes, Patricio,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects and add-on therapy with memantine, an N-methyl-d-aspartate receptor antagonist, approved for moderate-to-severe AD, may ameliorate such side effects. This was […]
The association between systemic inflammation and cognitive performance in the elderly: the Sydney Memory and Ageing Study
Trollor, Julian N.,
Smith, Evelyn,
Agars, Emmeline,
Kuan, Stacey A.,
Baune, Bernhard T.,
Campbell, Lesley,
Samaras, Katherine,
Crawford, John,
Lux, Ora,
Kochan, Nicole A.,
Brodaty, Henry,
Sachdev, Perminder
Inflammation may contribute to cognitive decline and dementia. This study examined the cross-sectional relationships between markers of systemic inflammation (C-reactive protein, interleukins-1β, -6, -8, -10, -12, plasminogen activator inhibitor, serum amyloid A, tumour necrosis factor-α and vascular adhesion molecule-1) and cognitive function in 873 non-demented community-dwelling elderly participants aged 70-90 years. Regression analyses were performed […]